Unknown

Dataset Information

0

I-1-deficiency negatively impacts survival in a cardiomyopathy mouse model.


ABSTRACT:

Aims

Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy, diastolic dysfunction and increased interstitial fibrosis. Current treatment is based on beta-adrenoceptor (AR) and calcium channel blockers. Since mice deficient of protein phosphatase-1 inhibitor-1 (I-1), an amplifier in beta-AR signalling, were protected from pathological adrenergic stimulation in vivo, we hypothesized that I-1 ablation could result in an improved outcome in a HCM mouse model.

Methods and results

We crossed mice deficient of I-1 with homozygous myosin-binding protein C knock-out (Mybpc3 KO) mice exhibiting cardiac dilatation and reduced survival. Unexpectedly, survival time was shorter in double I-1/Mybpc3 KO than in single Mybpc3 KO mice. Longitudinal echocardiographic assessment revealed lower fractional area change, and higher diastolic left ventricular inner dimensions and end-diastolic volumes in Mybpc3 KO than in WT mice. In comparison to Mybpc3 KO, double I-1/Mybpc3 KO presented higher left ventricular end-diastolic volumes, inner dimensions and ventricular surface areas with increasing differences over time. Phosphorylation levels of PKA-downstream targets and mRNA levels of hypertrophic markers did not differ between I-1/Mybpc3 KO and single Mybpc3 KO mice, except a trend towards higher beta-myosin heavy chain levels in double I-1/Mybpc3 KO.

Conclusion

The data indicate that interference with beta-AR signalling has no long-term benefit in this severe MYBPC3-related cardiomyopathy mouse model.

SUBMITTER: Friedrich FW 

PROVIDER: S-EPMC5497269 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

I-1-deficiency negatively impacts survival in a cardiomyopathy mouse model.

Friedrich Felix W FW   Sotoud Hannieh H   Geertz Birgit B   Weber Silvio S   Flenner Frederik F   Reischmann Silke S   Eschenhagen Thomas T   Carrier Lucie L   El-Armouche Ali A  

International journal of cardiology. Heart & vasculature 20150529


<h4>Aims</h4>Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy, diastolic dysfunction and increased interstitial fibrosis. Current treatment is based on beta-adrenoceptor (AR) and calcium channel blockers. Since mice deficient of protein phosphatase-1 inhibitor-1 (I-1), an amplifier in beta-AR signalling, were protected from pathological adrenergic stimulation in vivo, we hypothesized that I-1 ablation could result in an improved outcome in a HCM mouse model.<h4>  ...[more]

Similar Datasets

| S-EPMC5006183 | biostudies-literature
| S-EPMC6075362 | biostudies-literature
| S-EPMC5008411 | biostudies-literature
| S-EPMC7230052 | biostudies-literature
| S-EPMC10310307 | biostudies-literature
| S-EPMC6709902 | biostudies-literature
| S-EPMC9869410 | biostudies-literature
| S-EPMC2789639 | biostudies-literature
| S-EPMC6783488 | biostudies-literature
| S-EPMC8265075 | biostudies-literature